Global Contraceptive Devices Market Set To Grow To $18.7bn By 2022

Tuesday 20 February 2018, Amsterdam

The key player has launched a new pharma report Global Contraceptive Devices Market Forecast to 2027: Male Condoms, Female Condoms, Diaphragms, Sponges, Vaginal Rings, Subdermal/Contraceptive Implants, Intra-uterine Devices (IUDs), Copper IUD, Hormonal IUD.

The evolution of contraceptive devices has opened a new outlook in the healthcare industry. Growth rate exhibited by the contraceptive devices market despite the shortages and lack of awareness among the population in various countries, confirms the positive growth prospects going ahead. The contraceptive devices market is highly competitive and has reached maturity resulting in single digit growth rates of prominent devices such as condoms, diaphragms, vaginal rings, sponges, etc.

The lead analyst of the report commented “The global contraceptive devices market is expected to experience a significant growth over the forecast period. The main drivers for the growth include rapid growth in population, development of technologically advanced contraceptive devices, huge burden of sexually transmitted diseases and HIV, increasing adoption of contraceptive devices and supportive government authorities.

The rising prevalence of sexually transmitted diseases (STDs) is increasing the need of more innovative products in the contraceptive devices market. At present, condoms are the only contraceptive devices that prevent from the risk of sexually transmitted infections & HIV therefore; manufacturers across the globe are enormously investing in R&D to come up with a product that would be reminiscent of contraceptive condoms in the prevention of sexually transmitted infections & HIV along with unintended pregnancies and birth control.”

Leading companies featured in the report include Bayer AG, Reckitt Benckiser Group plc, Merck Sharp & Dohme Corp., Church & Dwight Co., Inc., Teva Pharmaceutical Industries, Ltd., Allergan plc, Ansell Limited (Now Humanwell), The Female Health Company (a division of VERU Inc.), Karex Industries, Mayer Laboratories, Kessel Medintim GmbH, Okamato Industries, Inc., Agile Therapeutics, Inc., Eurogine S.L.